Alentis Adds To Bank Balance And Rides The Claudin Wave
Series C Raises $105m
While most of the R&D attention in the hot space of claudins has focused on targeting CLDN18.2, the Swiss biotech believes its CLDN1 programs have the advantage of a broader expression profile.
